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Background
The etiology of GHD remains unknown in
most cases (Alatzoglou et al, 2009). RNPC3
mutations emerged as a novel cause of famil-
ial isolated GHD and pituitary hypoplasia
(Argente et al, 2014). RNPC3 encodes a 65-
kDa protein that is a structural component of
the U11/U12 small nuclear ribonucleoprotein
of the minor spliceosome (Verma et al,
2018). Mutations in RNPC3 lead to structural
destabilization of the 65-kDa protein,
impaired binding of U12 snRNA, and global
defects in splicing of U12-type introns
(Argente et al, 2014; Norppa et al, 2018).
We describe the effects of rhGH therapy
on growth, body composition, bone mineral
density (BMD), and bone microarchitecture
in the first three patients identified with this
condition.
Subjects and methods
Written informed consent was obtained
from all subjects and their parents for all
studies and their publication. Studies
conformed to the principles set out in the
WMA Declaration of Helsinki and the
Department of Health and Human Services
Belmont Report.
Three sisters were born to non-consan-
guineous average-height [target: 155.6
(0.99 SDS)] Romanian parents. The father
is a heterozygous carrier of a nonsense
mutation (c.1504C>T, p.R502X), and the
mother and only unaffected daughter are
heterozygous for a missense mutation in
RNPC3 (c.1320C>A, p.P474T). The three
affected girls, compound heterozygous for
both mutations, were born at term with
normal length and weight, developing
severe postnatal growth failure, typical
phenotypic features of GHD, and delayed
bone age (BA; Table 1 and Fig 1). They
were referred to our clinic at 15.5, 8.1, and
6.0 years of age with extremely short stature
(Table 1), undetectable serum IGF-1, IGFBP-
3 and GH after stimuli (insulin and cloni-
dine), and no clinical or hormonal signs of
associated pituitary hormone deficiencies.
Anterior pituitary hypoplasia was found in
MRI.
Daily subcutaneous rhGH (0.025–
0.035 mg/kg/day) was prescribed, with
regular clinical, laboratory, and BA (Greu-
lich & Pyle) evaluations.
Lumbar spine BMD (LS-BMD) and body
fat percentage were measured using dual-
energy X-ray absorptiometry (DXA Discov-
ery Wi, software version 13.3; Hologic, Inc.,
Waltham, MA, USA) before and 6 months,
1, and 6.5 years after rhGH therapy onset
(coefficient of variation 0.70). Data for BMD
were adjusted by height-for-age Z-score
(Zemel et al, 2010).
Trabecular bone structure (TBS) was
calculated from the same DXA acquisition
used for LS-BMD (TBS iNsight software,
v3.0; Medimaps, France). In children, there
is no international consensus of what consti-
tutes a normal or abnormal TBS. In adults,
TBS ≥ 1,350 is proposed to be normal,
values between 1,200 and 1,350 are consis-
tent with partially degraded bone, and TBS
≤ 1,200 indicates degraded bone (Silva et al,
2014).
Results
Growth, puberty, and biochemical evolution
Patient 1
At age 15.5 years, she was 125.5 cm (5.9
SDS) with proportional short stature, evident
central adiposity, typical facial features of
GHD (Fig 1A), no signs of pubertal develop-
ment (Tanner stage I), and retarded skeletal
maturation (3.5 years below chronological
age). On rhGH therapy, growth increased
drastically, particularly during the first
2 years [growth velocity (GV) 12.8 and
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6.0 cm/year, for ages 16.5 and 17.5, respec-
tively], achieving a height of 150.3 cm at
age 20 (after 4.5 years on therapy; Fig 1A).
Puberty started spontaneously shortly
after starting rhGH, with menarche at age
16. However, she had oligomenorrhea, with
sparse menstrual bleedings despite pubertal
FSH/LH and estradiol levels and a pubertal
shaped uterus with endometrium present at
ultrasonography (data not shown).
Patient 2
At treatment onset, she was 8.1 years and
100.4 cm (5.0 SDS), with no signs of
pubertal development (BA: 6.5 years) and
phenotypic features of GHD (Fig 1B). She
responded intensely to rhGH, especially
during the first 2 years (+14.2 and
+11.1 cm/year, respectively; Table 1). At
her last visit (age 14.5 years), she was
152.9 cm (0.7 SDS), close to her target
height (155.6  5 cm). She started puberty
(Tanner stage II) spontaneously at age
9.75 years, progressing to Tanner stage IV,
but without menarche up to her last visit.
Patient 3
She was 6 years old (BA 3.5 years) and
84.5 cm (6.7 SDS) at the onset of rhGH
(Fig 1C). Her GV also increased dramatically
during the first 2 years on treatment (+14.6
and +8.4 cm/year, respectively; Table 1).
She reached the 3rd centile in height at age
12.3 years, remaining prepubertal and with
BA retarded 1 year, with a 4.9 height-SDS
increase after 6.5 years on treatment.
Patients 1 and 2 normalized serum
IGFBP-3 after 1 month of rhGH and IGF-I
after 6 months. In the youngest sister, IGF-I
and IGFBP-3 did not reach reference ranges
until 1 year on rhGH, remaining normal up
to 4.5 years of therapy. In all patients, there
was a 6-month period during the fourth year
of therapy when GV, IGF-1, and IGFBP-3
levels decreased (Table 1 and Fig 1) due to
lack of treatment adherence.
The three siblings exhibited mild hyper-
cholesterolemia (positive paternal family
history) before therapy that did not change
significantly during treatment.
Body composition
The first year of rhGH therapy improved LS-
BMD and normalized TBS in all patients
(Table 1). BMD Z-score remained unchanged
after the 1-year DXA in patients 2 and 3, but
fully normalized in patient 1. An intense
lipolytic effect of rhGH treatment was
observed in patient 1 during her first year on
therapy, decreasing body fat from 44.1%
(+2.9 SDS) to 27.2% (+0.1 SDS) (Fig 1).
Discussion
In all three patients with GHD due to muta-
tions in RNPC3, rhGH treatment was highly
effective despite the severity of their short
Table 1. Anthropometric data at baseline and after rhGH therapy onset.
Chronological
age (bone age)
Height
(SDS)
Growth
velocity (SDS) DXA (baseline) DXA2 DXA3 DXA4
Patient 1
Baseline 15.5 (12.0) 125.5 (5.9) — Weight (kg) 36.7 36.8 35.9 61.3
1st year 16.5 (13.0) 137.8 (4.2) 12.8 (+31.0) BMI (kg/m2) 23.3 20.75 20.91 27.1
2nd year 17.5 (14.0) 143.8 (3.1) 6.0 (+21.0) BMD (g/cm2) 0.6440 0.733 0.781 1,050
3rd year 18.5 (14.0) 146.4 (2.6) 2.6 (+14.4) BMD (Z-score) 3.7 2.7 2.2 0.4
4th year 19.5 148.8 (2.2) 2.3 (+12.5) TBS 1,270 1,280 1,400 N.A.
Patient 2
Baseline 8.1 (6.5) 100.4 (5.0) — Weight (kg) 17.5 18.5 20.2 50.4
1st year 9.0 (7.5) 114.0 (3.2) 14.2 (+11.4) BMI (kg/m2) 17.4 15.75 14.76 20.81
2nd year 10.0 (9.0) 125.1 (2.0) 11.1 (+5.5) BMD (g/cm2) 0.478 0.515 0.523 0.825
3rd year 11.1 (10.5) 133.2 (1.5) 8.2 (+1.4) BMD (Z-score) 1.3 0.7 1.0 1.0
4th year 12.0 (11.3) 138.5 (1.6) 5.7 (1.2) TBS 1,260 1,270 1,360 N.A.
5th year 13.0 (12.5) 146.2 (1.2) 7.8 (+2.8)
6 year & 6 month 14.5 (13.5) 152.9 (0.7) 5.0 (+1.2)
Patient 3
Baseline 6.0 (3.5) 84.5 (6.7) — Weight (kg) 9.8 11.5 12.7 36
1st year 7.0 (5.0) 98.5 (4.4) 14.6 (+9.3) BMI (kg/m2) 13.7 15.77 14.76 18.90
2nd year 8.0 (6.5) 106.9 (3.6) 8.4 (+3.7) BMD (g/cm2) 0.397 0.446 0.470 0.678
3rd year 9.0 (7.5) 114.2 (3.2) 7.4 (+1.1) BMD (Z-score) 2.2 1.4 1.0 1.1
4th year 10.0 (8.8) 119.3 (2.9) 5.4 (+0.5) TBS 1,260 1,270 1,360 N.A.
5th year 10.9 (10.0) 126.4 (2.5) 7.1 (+1.3)
6 year & 6 month 12.3 (11.3) 137.5 (1.9) 7.4 (+0.5)
SDS, standard deviation score. Bone mineral density (BMD) and trabecular bone structure (TBS) in DXA (dual-energy absorptiometry analysis) in the three patients
before (baseline) and after 6 months (DXA2), 1 year (DXA3), and 6.5 years (DXA4) of rhGH therapy onset (patient 1 received 4.5 years of treatment, and patients 2
and 3 remain on treatment). All of the DXA data refer to lumbar spine (L1–L4) (N.A., not available).
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stature and considering that therapy was
started after age 15 in the eldest. The
improvement in height SDS after 4.5 (for the
eldest) to 6.5 years on rhGH was between
4.0 and 4.9 SDS, with the two younger
siblings continuing to grow. This change in
height SDS is higher than the average
response to rhGH in patients with isolated
GHD (Darendelier et al, 2011 and Argente
et al, 2014), but similar when compared
with severe isolated GHD (Ranke & Lind-
berg, 2010 and Argente et al, 2014). This
effect was maximum in patient 3, probably
because rhGH was started at a younger age
and her baseline height was more severely
compromised (Ranke & Lindberg, 2010).
However, the eldest sister increased her
height in 24.8 cm despite her advanced
chronological (15.5) and bone age
(12 years) at therapy onset, with growth
progressing even after menarche, achieving
a 21.4-cm pubertal growth spurt. However,
this late onset of treatment might have
compromised her adult height (0.9 SDS
below target height), which is below that
expected for her siblings with their height
centile close (patient 3) or above (patient 2)
their target and still growing on therapy.
The improvements in BMD and TBS
during the first year on therapy indicate that
the GH-induced rise in IGF-I is fundamental
for improving bone development, as we
recently reported in patients with PAPP-A2
deficiency (Hawkins-Carranza et al, 2018).
Follow-up of the two younger sisters is
required to determine whether BMD and
TBS completely normalize and to investigate
an eventual relationship between RNPC3
mutations and possible impairment of the
GnRH axis as suggested by the pubertal and
menstrual evolution in patients 1 and 2.
The extremely positive response to
exogenous GH treatment suggests that the
required receptors and downstream signal-
ing molecules are intact. Indeed, these
patients showed almost undetectable GH
levels after standard stimuli and basal IGF-I,
IGFBP-3, and ALS levels suggesting that the
lack of pituitary GH secretion is the underly-
ing cause for their growth failure. Moreover,
their lack of antibody production in response
to this treatment further indicates an intact
GH1 gene. The data and the pituitary hypo-
plasia observed in these patients highly
suggest that the minor spliceosome plays a
crucial role in the processing of genes
required for somatotroph development and
GH synthesis.
The positive family history of hyper-
cholesterolemia and lack of improvement
during rhGH replacement (even when the
lipolytic effect of rhGH was highly evident)
suggest that this finding is most likely inde-
pendent from GHD.
In summary, despite the fact that
the underlying mechanism by which the
RNPC3 mutations result in GHD is not
completely understood, rhGH dramatically
increased growth in three girls with severe
isolated GH deficiency due to a defective
minor spliceosome mRNA processing, deter-
mining a significant improvement in BMD,
microarchitecture of the bone, and body
composition.
A B
C
D
Figure 1. Growth charts of the three sisters after GH therapy.
Facial appearance at baseline and growth charts of patients 1 (A), 2 (B), and 3 (C). Blue circles represent height for
chronological age, whereas yellow triangles represent height for bone age. BA, bone age; CA, chronological age;
GH, start of recombinant growth hormone treatment; TH, target height. Faces of the patients reproduced with
permission. (D) Changes in body fat content and distribution showing the lipolytic effect of recombinant human
growth hormone treatment in patient 1 after 6 and 12 months of therapy from baseline. Reproduced with
permission.
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